FGF21 is also implicated in the development of extrahepatic cancers found more commonly in patients with NAFLD, including breast, colorectal, esophageal, and pancreatic, as well as hepatocellular carcinoma [42]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.